|Articles|September 10, 2004

Erythromycin Combined with Common Drugs May Increase Cardiac Death Risk

Patients who took the antibiotic erythromycin with medications that inhibit CYP3A drug enzymes, such as certain calcium-channel blockers, certain anti-fungal drugs, and some anti-depressants, had a five-times greater risk of sudden death from cardiac causes than patients who did not take the drugs at the same time, according to a new study co-funded by HHS Agency for Healthcare Research and Quality, Food and Drug Administration, and National Institutes of Health.

 

Erythromycin is a commonly used antibiotic because it is considered to be inexpensive and very safe. In the study, which is published in the Sept. 9, 2004 issue of the New England Journal of Medicine, Wayne A. Ray, PhD, and his colleagues at AHRQs Center for Education and Research on Therapeutics (CERT) at Vanderbilt University, did not find the same increased risk for patients who took CYP3A inhibitors with other antibiotics, such as amoxicillin, or for those who had taken erythromycin in the past. The CERTs program is a national initiative to increase the awareness of the benefits and risks of new, existing, or combined uses of therapeutics and devices.

 

This study provides critical scientific evidence that can be used to improve health care quality and safety by preventing potentially dangerous drug interactions, said AHRQ director Carolyn M. Clancy, MD. "These findings will help clinicians to make more informed choices about which antibiotics should be used with patients who are taking multiple medications.

 

Researchers reviewed medical records for the Tennessee Medicaid program and identified patients who had experienced sudden death from cardiac causes during the period Jan. 1, 1988, to Dec. 31, 1993. They reviewed prescriptions for erythromycin, amoxicillin, and other medications from computerized Medicaid pharmacy files that included the drug, dose, and total medication dispensed. Behavioral risk factors, such as smoking and a lack of physical activity, were not studied.

 

Researchers conclude that clinicians should avoid prescribing a combination of erythromycin and CYP3A inhibitors to patients at the same time because there are safer alternatives.

 

Source: Agency for Healthcare Research and Quality (AHRQ)    


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERISS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.